KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Treasury Shares (2016 - 2025)

Vertex Pharmaceuticals has reported Treasury Shares over the past 16 years, most recently at $4.8 million for Q4 2025.

  • Quarterly results put Treasury Shares at $4.8 million for Q4 2025, up 77.78% from a year ago — trailing twelve months through Dec 2025 was $4.8 million (up 77.78% YoY), and the annual figure for FY2025 was $4.8 million, up 77.78%.
  • Treasury Shares for Q4 2025 was $4.8 million at Vertex Pharmaceuticals, up from $2.7 million in the prior quarter.
  • Over the last five years, Treasury Shares for VRTX hit a ceiling of $7.3 million in Q4 2021 and a floor of $300000.0 in Q1 2024.
  • Median Treasury Shares over the past 5 years was $1.7 million (2024), compared with a mean of $2.2 million.
  • Biggest five-year swings in Treasury Shares: soared 1215.14% in 2021 and later tumbled 83.19% in 2022.
  • Vertex Pharmaceuticals' Treasury Shares stood at $7.3 million in 2021, then tumbled by 83.19% to $1.2 million in 2022, then grew by 5.95% to $1.3 million in 2023, then soared by 107.69% to $2.7 million in 2024, then soared by 77.78% to $4.8 million in 2025.
  • The last three reported values for Treasury Shares were $4.8 million (Q4 2025), $2.7 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.